Local Business Impacted by Large Chain Acquisition
You might have heard this kind of story before. A long-standing family-run business, beloved in the community, is shutting down after being bought by a big national retailer. These large chains, bolstered by significant market shares and favorable regulations from the federal government, tend to squeeze out smaller competitors, leaving local economies feeling a bit less vibrant.
This scenario is sadly familiar for independent pharmacies. They’re struggling with challenges related to drug costs and rebates that pharmacy benefit managers (PBMs) don’t adequately cover. PBMs, which were originally created to aid patients and manage drug costs, have morphed into entities that primarily enrich themselves, not the patients who need those life-saving medications. Loopholes and a lack of accountability have solidified a system that benefits these middlemen while increasing burdens on pharmacies.
Initially, PBMs were supposed to negotiate drug prices between manufacturers and pharmacies for the sake of patients. But over time, they began to keep these savings for themselves, prioritizing their financial interests over patient needs. This has resulted in hurdles to accessing essential medications, high co-pays, and an alarming lack of transparency. Patients often find themselves in the dark about a critical part of their healthcare.
The repercussions of this situation extend beyond local pharmacies; they affect the economy as a whole. PBMs are known for reimbursing independent pharmacies at rates lower than the cost of acquiring drugs, sometimes delaying payments for weeks or even months. Such practices lead to budget issues and create significant stress for local businesses. Moreover, PBMs impose retroactive fees under Medicare Part D, making it extremely difficult for these independent pharmacies to forecast their income accurately. If a business owner can’t predict costs, it disrupts everything.
These harmful practices have driven many independent pharmacies to close across the nation. This leaves so many Americans grappling not just with high co-pays for necessary medications but also losing access to the local healthcare providers they’ve relied on for years. Even though PBMs are seeing remarkable profits, totaling $7.3 billion in revenue over just five years, one out of three retail pharmacies has closed since 2010. These costs aren’t being exposed to the public, and it’s about time that our elected representatives advocate for patients everywhere.
There’s a glimmer of hope in Alabama, where legislative efforts are underway to tackle these practices and support local communities. In April 2025, the Alabama Legislature enacted S. 252, the Alabama Community Pharmacy Relief Act. This law mandates that PBMs reimburse pharmacies at Medicaid rates, closing one of the expensive loopholes that have long disadvantaged local pharmacies. It also promotes transparency and accountability within the PBM landscape, aiming for financial stability for independent community pharmacies and affordable pharmaceutical services for patients.
However, there’s still more to be done on a national scale. Several significant bills have been introduced in Congress, enjoying bipartisan support, aimed at resolving these issues comprehensively. The strong backing of this legislation highlights that this isn’t just political maneuvering; it’s about repairing a flawed system and safeguarding patients, employers, and independent pharmacists alike.
What started as a well-meaning initiative to negotiate costs on behalf of patients has become a game that mainly benefits a select few in the industry, harming patients, employers, and small businesses. PBMs have acquired too much power, maintaining practices that lack transparency and are ultimately irresponsible toward the systems and patients they were meant to serve.
Independent pharmacies have been essential healthcare providers for many Americans, and their valuable contributions deserve recognition and protection. It’s time for elected officials to actively defend small businesses and patients against the predatory behaviors of PBMs.
